<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="16990">Bilirubin</z:chebi> is a potent <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, however, uncertainty surrounds its physiological importance </plain></SENT>
<SENT sid="1" pm="."><plain>Individuals with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> (GS) have increased circulating <z:chebi fb="0" ids="16990">bilirubin</z:chebi> and a reduced prevalence of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to investigate mechanisms that may link <z:chebi fb="0" ids="16990">bilirubin</z:chebi> to protection from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> seen in GS by examining markers of <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and <z:mp ids='MP_0003674'>oxidative stress</z:mp> status and the susceptibility of serum to oxidation </plain></SENT>
<SENT sid="3" pm="."><plain>Nine individuals with GS and twelve controls, matched for age, height and weight, were assessed for plasma <z:chebi fb="11" ids="22586">antioxidant</z:chebi> status, red blood cell <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzyme activities, plasma malondialdehyde, the susceptibility of serum to copper (<z:chebi fb="0" ids="29036">Cu(2+)</z:chebi>) induced oxidation and blood <z:chebi fb="23" ids="18059">lipid</z:chebi> profile </plain></SENT>
<SENT sid="4" pm="."><plain>Individuals with GS had significantly elevated unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> (GS: 26.0+/-6.4; control: 9.7+/-3.0 micromol/L; P&lt;0.001), increased trolox equivalent <z:chebi fb="11" ids="22586">antioxidant</z:chebi> capacity (GS: 1.59+/-0.07; control: 1.52+/-0.07 mmol/L trolox Equ; P=0.035) and ferric reducing ability of plasma (GS: 1.09+/-0.16; control: 0.92+/-0.14 mmol/L Fe(2+) Equ; P=0.024) </plain></SENT>
<SENT sid="5" pm="."><plain>The lag phase of serum oxidation was significantly longer in the GS group (GS: 121.4+/-10.5; control: 106.8+/-14.6 min; P=0.020) and was positively correlated with the <z:chebi fb="0" ids="16990">bilirubin</z:chebi> concentration (r=0.451, P=0.040) </plain></SENT>
<SENT sid="6" pm="."><plain>A trend toward elevated <z:chebi fb="17" ids="39025">HDL</z:chebi>:<z:chebi fb="15" ids="39026">LDL</z:chebi> ratio was observed in GS (GS 0.96+/-0.31; control: 0.73+/-0.21; P=0.072) </plain></SENT>
<SENT sid="7" pm="."><plain>In summary, individuals with GS have an increased circulating <z:chebi fb="11" ids="22586">antioxidant</z:chebi> status and an improved resistance to serum oxidation which may partially explain their reduced prevalence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
</text></document>